Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of CPX-POM in Advanced Solid Tumors
NCT03348514Phase 1Completed
- Sponsor
- CicloMed LLC
- Start
- Jan 2018
- Primary completion
- May 2020
- Modality
- Allosteric Modulators, Orthosteric Ligands, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of fosciclopirox in solid tumor (advanced stage) (8 arms), sponsored by CicloMed LLC. Primary endpoints: Dose Limiting Toxicities up to 22 days and Maximum Tolerated Dose. Started Jan 2018; status: completed.
02
Drugs
fosciclopirox
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03348514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03348514.